• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives.寻常痤疮的口服抗生素治疗:药代动力学和药效学视角
J Clin Aesthet Dermatol. 2011 Feb;4(2):40-7.
2
Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy.沙瑞司亭治疗寻常痤疮:基于体重的给药理由和饮食摄入对临床疗效的有限影响。
Dermatol Ther. 2022 Mar;35(3):e15275. doi: 10.1111/dth.15275. Epub 2021 Dec 30.
3
BPX-01 Minocycline Topical Gel Shows Promise for the Treatment of Moderate-to-severe Inflammatory Acne Vulgaris.BPX-01米诺环素外用凝胶对中重度寻常性炎性痤疮的治疗显示出前景。
J Clin Aesthet Dermatol. 2018 Nov;11(11):25-35. Epub 2018 Nov 1.
4
Minocycline for acne vulgaris: efficacy and safety.米诺环素治疗寻常痤疮:疗效与安全性。
Cochrane Database Syst Rev. 2003(1):CD002086. doi: 10.1002/14651858.CD002086.
5
Oral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review.寻常痤疮的口服抗菌治疗:一项基于证据的综述。
Am J Clin Dermatol. 2017 Aug;18(4):469-490. doi: 10.1007/s40257-017-0267-z.
6
Systemic antibiotic therapy of acne vulgaris.寻常痤疮的全身抗生素治疗。
J Dtsch Dermatol Ges. 2006 Oct;4(10):828-41. doi: 10.1111/j.1610-0387.2006.06053.x.
7
Minocycline for acne vulgaris: efficacy and safety.米诺环素治疗寻常痤疮:疗效与安全性。
Cochrane Database Syst Rev. 2000(2):CD002086. doi: 10.1002/14651858.CD002086.
8
Common and alternate oral antibiotic therapies for acne vulgaris: a review.寻常痤疮的常见及替代口服抗生素疗法:综述
J Drugs Dermatol. 2007 Sep;6(9):873-80.
9
Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.随机对照多治疗比较,为痤疮抗菌治疗的选择提供成本效益依据。
Health Technol Assess. 2005 Jan;9(1):iii-212. doi: 10.3310/hta9010.
10
Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris.口服四环素治疗寻常痤疮的抗生素耐药风险
Antibiotics (Basel). 2022 Jul 30;11(8):1032. doi: 10.3390/antibiotics11081032.

引用本文的文献

1
Decoding Acne Vulgaris: Insights into Pathogenesis, Treatment Modalities, Diagnosis and Recent Advancements.解读寻常痤疮:对发病机制、治疗方式、诊断及最新进展的见解
Recent Adv Inflamm Allergy Drug Discov. 2025;19(1):18-30. doi: 10.2174/0127722708312980240718093537.
2
Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies.探索痤疮治疗:从病理生理学机制到新兴疗法。
Int J Mol Sci. 2024 May 13;25(10):5302. doi: 10.3390/ijms25105302.
3
Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity.与米诺环素相比,寻常痤疮抗生素丝氨酸环素的血脑屏障穿透性降低,这与较低的亲脂性相对应。
Front Med (Lausanne). 2022 Dec 8;9:1033980. doi: 10.3389/fmed.2022.1033980. eCollection 2022.
4
Minocycline Extended-Release Comparison with Doxycycline for the Treatment of Rosacea: A Randomized, Head-to-Head, Clinical Trial.米诺环素缓释剂与多西环素治疗酒渣鼻的比较:一项随机、直接比较的临床试验。
J Clin Aesthet Dermatol. 2021 Dec;14(12):16-23.
5
Foray into Concepts of Design and Evaluation of Microemulsions as a Modern Approach for Topical Applications in Acne Pathology.初探微乳剂的设计与评价概念,微乳剂是痤疮病理学局部应用的一种现代方法。
Nanomaterials (Basel). 2020 Nov 19;10(11):2292. doi: 10.3390/nano10112292.
6
Oral Antibiotic Treatment Options for Acne Vulgaris.寻常痤疮的口服抗生素治疗选择
J Clin Aesthet Dermatol. 2020 Sep;13(9):26-32. Epub 2020 Sep 1.
7
Oral Antibiotics for Acne.口服抗生素治疗痤疮。
Am J Clin Dermatol. 2021 Mar;22(2):193-204. doi: 10.1007/s40257-020-00560-w.
8
The Antibiotic Susceptibility Profile of Cutibacterium Acnes in Maltese Patients with Acne.马耳他痤疮患者中痤疮丙酸杆菌的抗生素敏感性概况
J Clin Aesthet Dermatol. 2020 Jun;13(6):11-16. Epub 2020 Jun 1.
9
Growth Inhibitory Activity of Leaf Extracts Against .叶提取物对……的生长抑制活性
Front Pharmacol. 2019 Oct 15;10:1206. doi: 10.3389/fphar.2019.01206. eCollection 2019.
10
Meeting the Challenges of Acne Treatment in Asian Patients: A Review of the Role of Dermocosmetics as Adjunctive Therapy.应对亚洲患者痤疮治疗的挑战:皮肤美容化妆品作为辅助治疗作用的综述
J Cutan Aesthet Surg. 2016 Apr-Jun;9(2):85-92. doi: 10.4103/0974-2077.184043.

本文引用的文献

1
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.痤疮管理的新见解:改善痤疮结局全球联盟小组的最新进展
J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50. doi: 10.1016/j.jaad.2009.01.019.
2
Optimizing use of oral antibiotics in acne vulgaris.寻常痤疮口服抗生素的优化使用
Dermatol Clin. 2009 Jan;27(1):33-42. doi: 10.1016/j.det.2008.07.006.
3
Can we define acne as a chronic disease? If so, how and when?我们能将痤疮定义为一种慢性疾病吗?如果可以,该如何定义以及何时定义呢?
Am J Clin Dermatol. 2008;9(5):279-84. doi: 10.2165/00128071-200809050-00001.
4
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.预测药物处置、吸收/消除/转运体相互作用以及食物对药物吸收的影响。
Adv Drug Deliv Rev. 2008 Mar 17;60(6):717-33. doi: 10.1016/j.addr.2007.08.043. Epub 2007 Nov 28.
5
Intestinal permeability and its relevance for absorption and elimination.肠道通透性及其与吸收和排泄的相关性。
Xenobiotica. 2007 Oct-Nov;37(10-11):1015-51. doi: 10.1080/00498250701704819.
6
Safety and efficacy of a new extended-release formulation of minocycline.米诺环素新缓释制剂的安全性与有效性
Cutis. 2006 Oct;78(4 Suppl):21-31.
7
Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris.新型每日一次缓释米诺环素治疗寻常痤疮的剂量范围疗效。
Cutis. 2006 Oct;78(4 Suppl):11-20.
8
Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets.盐酸米诺环素片新缓释制剂的关键生物利用度特征
Cutis. 2006 Oct;78(4 Suppl):6-10.
9
Anti-inflammatory activity of tetracyclines.四环素的抗炎活性。
Dermatol Clin. 2007 Apr;25(2):133-5, v. doi: 10.1016/j.det.2007.01.012.
10
Systemic antibiotic therapy of acne vulgaris.寻常痤疮的全身抗生素治疗。
J Dtsch Dermatol Ges. 2006 Oct;4(10):828-41. doi: 10.1111/j.1610-0387.2006.06053.x.

寻常痤疮的口服抗生素治疗:药代动力学和药效学视角

Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives.

作者信息

Leyden James J, Del Rosso James Q

出版信息

J Clin Aesthet Dermatol. 2011 Feb;4(2):40-7.

PMID:21386956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3050614/
Abstract

OBJECTIVE

To review data on pharmacokinetic factors that influence the absorption and tissue distribution for individual antibiotic agents to better inform clinicians on rational dosing considerations of oral antibiotics for the treatment of acne vulgaris. The focus is placed on the most commonly prescribed oral antibiotics for acne vulgaris, the tetracyclines. Dose-response is also reviewed.

DESIGN AND METHODS

This review describes factors affecting the absorption, distribution, and target tissue penetration of the most frequently prescribed oral antibiotics for the treatment of acne vulgaris, the tetracyclines. Articles cited were identified by a search of PubMed covering the period from January 1, 2000, to November 15, 2010. Reference lists in articles identified in this search were searched manually for additional references of interest.

RESULTS

Pharmacokinetic factors that may influence outcomes in antibiotic therapy for acne vulgaris include drug solubility, gastrointestinal permeability, systemic absorption, tissue distribution, and target tissue penetration. In particular, drugs that are highly soluble and highly permeable are well absorbed and widely distributed. Drugs that are more lipophilic are believed to penetrate better into the lipid-rich sebaceous follicular tissues, where the therapeutic target, Propionibacterium acnes, resides. Food intake and differences in patient body weight can also alter antibiotic absorption and distribution, potentially resulting in differences in efficacy and tolerability. Dose-response data with oral antibiotics, including the tetracyclines, is scant. Pharmacokinetic studies completed with extended-release minocycline have allowed for assessment of interindividual differences in drug absorption, a consideration that may influence therapeutic response and/or predilection for adverse effects. Dose-response pharmacokinetic data is not currently available with other tetracyclines.

CONCLUSION

An understanding of the differences in absorption (with and without meals or other ingestants), distribution, and target tissue penetration among oral tetracyclines is valuable for clinicians, as such factors may influence outcomes in patients treated for acne vulgaris.

摘要

目的

回顾影响个体抗生素吸收和组织分布的药代动力学因素,以便更好地为临床医生提供关于治疗寻常痤疮口服抗生素合理给药考虑的信息。重点关注治疗寻常痤疮最常用的口服抗生素——四环素类。同时也回顾了剂量反应情况。

设计与方法

本综述描述了影响治疗寻常痤疮最常用的口服抗生素——四环素类吸收、分布及靶组织渗透的因素。通过检索2000年1月1日至2010年11月15日期间的PubMed确定引用的文章。手动检索该检索中确定的文章的参考文献列表以获取其他相关参考文献。

结果

可能影响寻常痤疮抗生素治疗效果的药代动力学因素包括药物溶解度、胃肠道通透性、全身吸收、组织分布和靶组织渗透。特别是,高溶解度和高通透性的药物吸收良好且分布广泛。亲脂性更强的药物被认为能更好地渗透到富含脂质的皮脂腺滤泡组织中,而治疗靶点痤疮丙酸杆菌就存在于该组织中。食物摄入和患者体重差异也会改变抗生素的吸收和分布,可能导致疗效和耐受性的差异。包括四环素类在内的口服抗生素的剂量反应数据很少。用缓释米诺环素完成的药代动力学研究使得能够评估个体间药物吸收的差异,这一因素可能影响治疗反应和/或不良反应倾向。目前其他四环素类药物尚无剂量反应药代动力学数据。

结论

了解口服四环素类药物在吸收(有无食物或其他摄入物)、分布和靶组织渗透方面的差异对临床医生很有价值,因为这些因素可能影响寻常痤疮患者的治疗效果。